Background:  Neurabin 2, also called spinophilin, interacts with actin and PP-1 in dendritic spines of the central nervous system. The gene encoding human neurabin 2 maps to chromosome 17q21-q22. The structural characteristics of neurabin 2 include one F-actin binding domain at the N-terminal region, a predicted coiled-coil struture at the C-terminal, one PDZ domain at the middle region, and a domain known to interact with transmembrane proteins. Neurabin 2 bundles actin fliaments in vitro. In vivo, spinophilin localizes to the cortical sites of actin filaments and to the sites of active membrane remodelling. Neurabin 2 also forms a complex with the catalytic subunit of PP1 and modulates PP1 enzymatic activity in vitro. Neurabin 2 localizes to the head of dendritic spines and aids in the ability of PP-1 to regulate the activity of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-asparate (NMDA) receptors. In this manner, neurabin 2 modulates both glutamatergic synaptic transmission and dendritic morphology. Synergistic interactions between spinophilin and human tumor supressor ARF suggest a role for neurabin 2 in cell growth.

Description: Rabbit polyclonal to Neurabin 2

Immunogen: KLH conjugated synthetic peptide derived from Neurabin 2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 89 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.